The identification of effective systemic medications for prostate cancer has been relatively recent and this field is now making exciting advances. Speaking from the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK, Robert Jones, MD of the Beatson West of Scotland Cancer Centre, Glasgow, UK provides a captivating overview of the results of the recent STAMPEDE (NCT00268476) and LATITUDE (NCT01715285) trials of docetaxel and abiraterone, respectively, for patients with metastatic and/or high-risk disease. Dr Jones then discusses the preliminary results of which drug is better for this group and upcoming clinical trials of hormone receptor antagonists for nonmetastatic castration-resistant prostate cancer.
Exciting advances in systemic therapy for prostate cancer: docetaxel and abiraterone
